Skip to main content
OpenTrials
Completed

NCT Number: NCT05149079

Effects of a Marine Protein Hydrolysate in Healthy Adults

This randomized, double blind, controlled trial investigates changes in the cardiovascular index (triacylglycerol/HDL-cholesterol × waist/hip ratio) after 12 weeks of marine protein hydrolysate (MPH) or whey protein powder (placebo) supplementation in adult healthy persons. Additionally, the study investigates potential effects on plasma parameters of metabolic health including lipids, glucose, inflammatory parameters and redox state, as well as associations between dietary MPH and body weight, abdominal obesity, body composition, and gut microbiota composition. Finally, putative end-products of diet-microbial interactions (TMAO and short-chain fatty acids) with CVD risk factors and biomarkers of mitochondrial function are examined.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

20 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Research Unit for Health Trials

Bergen, 5009, Norway

About this study

Marine protein sources, including fish and fish protein hydrolysates, may have particular health benefits. Health benefits from fish consumption have been attributed to the n-3 polyunsaturated fatty acids, in particular eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Proteins from marine sources may contain valuable bioactive components, with amino acid composition and protein profiles that differ from terrestrial sources. Generally, the dietary source of protein can affect cellular energy metabolism, and hydrolyzed peptides can have potent and specific bioactive potential.

Rest raw materials (RRM) from cod (Fjordlaks AS, Norway) are used for the hydrolysis production (Food Grade). Freshly minced RRM were treated with enzymes optimized to generate bioactive hydrolysates using facilities and techniques approved for human consumption. The investigational products are given in a dose of 18 g protein per day, corresponding to the protein content of a standard meal, and similar to doses recommended in a range of protein supplements.

The study enrolls around 70 men and women age of 20-80 years with waist circumference of < 102 cm for men and < 88 cm for women. Prospective study participants were informed of the study and invited to participate through advertising primarily in social media (Facebook advertisement, geographically limited to 12 km surrounding the city centers of Bergen and Ålesund). Participants provided written informed consent, and were screened via self-reporting in an online form in EasyTrial hosted by the Research Unit for Clinical Trials at the University of Bergen. Data collection by the study staff at baseline verifies inclusion and exclusion criteria and participant eligibility prior to randomization. The potential participants are informed about practical details at a digital or physical meeting 1-2 weeks prior to baseline.

Groups of participants (40-60% males/females) are block randomized to the two treatments using randomly selected block sizes, and stratified according to sex.

The participants are given a container with the powder sufficient for the entire study period, and a spoon to measure the intake at breakfast (6 g), lunch (6 g) and supper (6 g), or morning (9 g) and evening (9 g) according to individual preference. The patients will mix the powder products in water or mineral water. Flavours have been masked by supplementation with beet powder, and mixing 0.5 g fish hydrolysate per serving in the placebo, to minimize differences in taste of the placebo and active product.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy female and male subjects at age 20-80 years old understanding Norwegian oral and written information
  • Waist circumference for males < 102 cm and females < 88 cm

Exclusion criteria

  • Pregnancy or lactation
  • Having used high-dose omega-3 PUFA supplements (>2 g/day) less than 28 days prior to randomization
  • Use of corticosteroids that will influence protein metabolism
  • Antibiotic treatment previous 3 months
  • Alcohol or drug abuse or any conditions associated with poor compliance
  • Medical diagnosis of malabsorption disorders, Crohn's disease, or lactose intolerance
  • Scheduled hospitalization during the course of the study that could compromise the study
  • Diabetes type I or II, serious high blood pressure at screening, serious infections, diseases requiring medication that can influence the study
  • Known or suspected sensitivity or allergic reactions to the IMP or excipients
  • Presence of other major medical or psychiatric illness that would affect the ability to participate in the study or put the subject at increased risk
  • Intake of statins. If needed to obtain the recruitment goals, we will accept people using a low dose of statin

Treatment and study plan

Cod protein hydrolysate

Dietary Supplement

Rest raw materials (RRM) from cod (Fjordlaks AS, Norway) are used for the hydrolysis production (Food Grade). Freshly minced RRM is treated wth enzymes optimized to generate bioactive hydrolysates using facilities and techniques approved for human consumption.

Placebo

Dietary Supplement

Whey protein powder, commercially available

Other names: Whey protein powder

Primary outcomes

  1. Changes in the cardiovascular index (triacylglycerol/high density lipoprotein (HDL)-cholesterol × waist/hip ratio)

    Time frame: Baseline to 12 weeks

    Triacylclygerol and HDL-cholesterol concentrations will be measured in serum. Waist and hip circumference will be measured using anthropometric tape over light clothing. For waist circumference, the minimum circumference between the iliac crest and the rib cage will be used. For waist circumference the circumference at the level of the greatest protrusion of the buttocks is used.

Secondary outcomes

  1. Changes in the Quick1 index, a surrogate marker of insulin sensitivity

    Time frame: Baseline to 12 weeks

    Measured in serum and calculated as 1 / (log(fasting insulin μU/mL) + log(fasting glucose mg/dL)

  2. Changes in fasting insulin

    Time frame: Baseline to 12 weeks

    Measured in serum

  3. Changes in fasting insulin C-peptide

    Time frame: Baseline to 12 weeks

    Measured in serum

  4. Changes in fasting glucose

    Time frame: Baseline to 12 weeks

    Measured in serum

  5. Changes in total cholesterol

    Time frame: Baseline to 12 weeks

    Measured in serum

  6. Changes in non-high density lipoprotein (HDL) cholesterol

    Time frame: Baseline to 12 weeks

    Measured in serum

  7. Changes in non-esterified fatty acids (NEFA)

    Time frame: Baseline to 12 weeks

    Measured in serum

  8. Changes in triacylglycerol (TAG)

    Time frame: Baseline to 12 weeks

    Measured in serum

  9. Changes in gut microbiota composition

    Time frame: Baseline to 12 weeks

    Measured by 16S sequencing

  10. Changes in short chained fatty acids (SCFA)

    Time frame: Baseline to 12 weeks

    Faecal SCFA concentrations calculated as (mmol/L) × wet faecal weight x faecal moisture content (g/100 g) × 10

  11. Changes in fat mass/fat free mass ratio

    Time frame: Baseline to 12 weeks

    Body composition measured by bioimpedance analysis

  12. Changes in waist-hip ratio

    Time frame: Baseline to 12 weeks

    Waist and hip circumference will be measured using anthropometric tape over light clothing. For waist circumference, the minimum circumference between the iliac crest and the rib cage will be used. For waist circumference the circumference at the level of the greatest protrusion of the buttocks is used

  13. Changes in waist-to-height ratio (WHtR)

    Time frame: Baseline to 12 weeks

    Waist circumference will be measured using anthropometric tape over light clothing. Hight will be measured using a stadiometer. For waist circumference, the minimum circumference between the iliac crest and the rib cage will be used.

  14. Changes in blood pressure

    Time frame: Baseline to 12 weeks

    Blood pressure measurement will be performed manually by a trained nurse using standard equipment

  15. Changes in heart rate

    Time frame: Baseline to 12 weeks

    Heart rate will be determined manually by a trained nurse

  16. Changes in glucagon-like peptide 1 (GLP-1, hormone involved in appetite and metabolism regulation)

    Time frame: Baseline to 12 weeks

    Measured in plasma by ELISA (enzyme-linked immunosorbent assay)

  17. Changes in gastric inhibitory polypeptide (GIP, hormone involved in metabolism regulation)

    Time frame: Baseline to 12 weeks

    Measured in plasma by ELISA (enzyme-linked immunosorbent assay)

  18. Changes in ghrelin (hormone involved in appetite regulation)

    Time frame: Baseline to 12 weeks

    Measured in plasma by ELISA (enzyme-linked immunosorbent assay)

Sponsors and collaborators

Lead sponsor

University of Bergen

Other

Collaborators

  • Alesund Hospital
  • Haukeland University Hospital
  • Norwegian University of Science and Technology

Registry information

Official study title

Randomized, Double Blind, Placebo Controlled Clinical Study to Investigate the Effect of a Marine Protein Hydrolysate in Healthy Adults

Acronym: MARPEP

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Dec 8, 2021
Registry last updated
Dec 8, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.